COVID-19 in HSCT recipients: a collaborative study of the Brazilian Society of Marrow Transplantation (SBTMO).
Liane Esteves DaudtMariana Cristina Moraes CorsoMariana Nassif KerbauyLuiz Henrique Dos Santos de AssisCiliana RechenmacherIago ColturatoFernanda Rodrigues BarbieriVanderson RochaLivia MarianoJulia Lopes GarciaVanessa Esther Cavalcanti Barreto DantasGisele LothVaneuza Araujo Moreira FunkePolliany Roberta Dorini PelegrinaFernando Barroso DuarteRoberto Luiz da SilvaMarco Aurelio Salvino AraújoFabianne Altruda de Moraes Costa CarlesseAna Virginia Lopes de SousaLuana Azevedo MaiaJuliana Folloni FernandesCelso Arrais RodriguesCarmem Maria Sales BonfimLeticia Navarro Gordan Ferreira MartinsRosana CipolottiErick Menezes XavierAlessandra Araújo GomesHugo Manuel Paz MoralesAnderson J SimioniVictor Jablonski SoaresMariana Bohns MichalowskiNelson HammerschlakClarisse Martins MachadoPublished in: Bone marrow transplantation (2022)
In the COVID-19 scenario, patients undergoing hematopoietic stem cell transplantation (HSCT) infected with SARS-CoV-2 may have an increased risk of death. Through a national multicenter study, we aimed to describe the impact of COVID-19 on the survival of HSCT recipients in Brazil. Eighty-six patients with a confirmed diagnosis of SARS-CoV-2 (92% by RT-PCR) were included. There were 24 children and 62 adults receiving an autologous (n = 25) and allogeneic (n = 61) HSCT for malignant (n = 72) and non-malignant (n = 14) disorders. Twenty-six patients died, (10 on autologous (38%) and 16 patients (62%) on allogeneic group). The estimated overall survival (OS) at day 40 was 69%. Adults had decreased OS compared to children (66% vs 79%, p = 0.03). The severity of symptoms at the time of diagnosis, ECOG score, laboratory tests (C-reactive protein, urea values) were higher in patients who died (p < 0.05). In conclusion, HSCT recipients infected with SARS-CoV-2 have a high mortality rate mainly in adults and patients with critical initial COVID-19 presentation. These findings show the fragility of HSCT recipients with SARS-CoV-2 infection. Therefore, the importance of adherence to preventive measures is evident, in addition to prioritizing the vaccination of family members and the HSCT team.
Keyphrases
- sars cov
- hematopoietic stem cell
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- bone marrow
- ejection fraction
- newly diagnosed
- patients undergoing
- stem cell transplantation
- young adults
- chronic kidney disease
- peritoneal dialysis
- cell therapy
- kidney transplantation
- type diabetes
- stem cells
- palliative care
- mesenchymal stem cells
- coronary artery disease
- low dose
- cardiovascular disease
- risk factors
- weight loss
- insulin resistance
- adipose tissue